| 1. |
Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res, 2017, 29(1): 1-10.
|
| 2. |
陳萬青, 鄭榮壽, 張思維, 等. 2013 年中國老年人群惡性腫瘤發病和死亡分析. 中華腫瘤雜志, 2017, 39(1): 60-66.
|
| 3. |
Sk?i?ková J, Kadlec B, Venclí?ek O. Non-small cell lung cancer. Vnitr Lek, 2018, 63(11): 861-874.
|
| 4. |
Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 2013, 13: 158.
|
| 5. |
Wang B, He YJ, Tian YX, et al. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer Prev, 2014, 15(22): 9611-9614.
|
| 6. |
Zhao W, Yu HX, Han ZF, et al. Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol, 2015, 8(8): 9506-9511.
|
| 7. |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2016, 11(1): 39-51.
|
| 8. |
Zhang ZH, Han YW, Liang H, et al. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med, 2015, 4(11): 1633-1638.
|
| 9. |
吳勤如, 劉飛. 血清 TK1、CEA、CYFRA21-1 聯合檢測對非小細胞肺癌的診斷價值. 國際檢驗醫學雜志, 2017, 38(20): 2921-2923.
|
| 10. |
焦鑫, 何思春, 萬紹恒, 等. 腫瘤標志物在肺癌診斷、預后預測中的臨床價值. 中國老年學雜志, 2019, 39(4): 811-814.
|
| 11. |
武標, 徐麗麗, 李玉生. D-二聚體檢測對肺癌的臨床應用價值分析. 中國實驗診斷學, 2019, 23(6): 1045-1046.
|
| 12. |
趙雋, 韓宇, 金高娃, 等. 纖維蛋白原預測晚期非小細胞肺癌化療的療效及預后. 現代腫瘤醫學, 2018, 26(20): 3228-3231.
|
| 13. |
Wang H, Zhang X, Liu X, et al. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer. J Cancer Res Ther, 2016, 12(1): 355-358.
|
| 14. |
Yao Y, Xu Q. Progress in the study of cancer-associated venous thromboembolism. Vascular, 2021, 29(3): 408-414.
|
| 15. |
程彬彬. D-二聚體、纖維蛋白原在晚期肺癌患者的水平及臨床意義. 世界最新醫學信息文摘, 2018, 18(30): 23-25.
|
| 16. |
史博文, 岳東升, 孫冰生, 等. 治療前血漿纖維蛋白原及 D-二聚體水平聯合預測晚期非小細胞肺癌患者預后. 天津醫藥, 2017, 45(4): 376-380.
|
| 17. |
Chen F, Wang MJ, Li J, et al. Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer. Tumour Biol, 2015, 36(12): 9201-9207.
|
| 18. |
武二偉, 司志剛, 王琰, 等. 血漿 D-二聚體及纖維蛋白原水平與肺癌臨床病理類型及預后的相關性. 實用醫藥雜志, 2019, 36(6): 487-489.
|
| 19. |
Qi Y, Fu J. Research on the coagulation function changes in non small cell lung cancer patients and analysis of their correlation with metastasis and survival. J BUON, 2017, 22(2): 462-467.
|
| 20. |
張啟貴, 林建伯. NSE、CYFRA21-1 和 FIB 聯合檢測對非小細胞肺癌患者臨床意義. 中國現代醫生, 2017, 55(35): 29-31.
|